Generics in Europe
Published: August 2013 · Publisher: MarketLine
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The European generics market had total revenues of $41.2bn in 2012, representing a compound annual growth rate (CAGR) of 4.8% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 1.8% between 2008-2012, to reach a total of 65.8% of total pharma volume in 2012.
*The performance of the market is forecast to accelerate, with an anticipated CAGR of 5% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $52.7bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Europe
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Europe economy
Key Questions Answered
What was the size of the Europe generics market by value in 2012?
What will be the size of the Europe generics market in 2017?
What factors are affecting the strength of competition in the Europe generics market?
How has the market performed over the last five years?
What are the main segments that make up Europe's generics market?
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The European generics market had total revenues of $41.2bn in 2012, representing a compound annual growth rate (CAGR) of 4.8% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 1.8% between 2008-2012, to reach a total of 65.8% of total pharma volume in 2012.
*The performance of the market is forecast to accelerate, with an anticipated CAGR of 5% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $52.7bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Europe
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Europe economy
Key Questions Answered
What was the size of the Europe generics market by value in 2012?
What will be the size of the Europe generics market in 2017?
What factors are affecting the strength of competition in the Europe generics market?
How has the market performed over the last five years?
What are the main segments that make up Europe's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Novartis AG, Sanofi and STADA Arzneimittel AG
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Threat of substitutes 19
Degree of rivalry 20
Leading Companies 21
Bayer AG 21
Novartis AG 25
Sanofi 29
STADA Arzneimittel AG 32
Appendix 35
Methodology 35
Industry associations 36
Related research 36
LIST OF TABLES
Table 1: Europe generics market value: $ million, 2008–12 9
Table 2: Europe generics market volume: % of total pharma volume, 2008–12 10
Table 3: Europe generics market geography segmentation: $ million, 2012 11
Table 4: Europe generics market value forecast: $ million, 2012–17 12
Table 5: Europe generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 21
Table 7: Bayer AG: key financials ($) 22
Table 8: Bayer AG: key financials (€) 22
Table 9: Bayer AG: key financial ratios 23
Table 10: Novartis AG: key facts 25
Table 11: Novartis AG: key financials ($) 26
Table 12: Novartis AG: key financial ratios 27
Table 13: Sanofi: key facts 29
Table 14: Sanofi: key financials ($) 30
Table 15: Sanofi: key financials (€) 30
Table 16: Sanofi: key financial ratios 30
Table 17: STADA Arzneimittel AG: key facts 32
Table 18: STADA Arzneimittel AG: key financials ($) 33
Table 19: STADA Arzneimittel AG: key financials (€) 33
Table 20: STADA Arzneimittel AG: key financial ratios 33
LIST OF FIGURES
Figure 1: Europe generics market value: $ million, 2008–12 9
Figure 2: Europe generics market volume: % of total pharma volume, 2008–12 10
Figure 3: Europe generics market geography segmentation: % share, by value, 2012 11
Figure 4: Europe generics market value forecast: $ million, 2012–17 12
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in Europe, 2012 14
Figure 7: Drivers of buyer power in the generics market in Europe, 2012 16
Figure 8: Drivers of supplier power in the generics market in Europe, 2012 17
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2012 18
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2012 19
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2012 20
Figure 12: Bayer AG: revenues & profitability 23
Figure 13: Bayer AG: assets & liabilities 24
Figure 14: Novartis AG: revenues & profitability 27
Figure 15: Novartis AG: assets & liabilities 28
Figure 16: Sanofi: revenues & profitability 31
Figure 17: Sanofi: assets & liabilities 31
Figure 18: STADA Arzneimittel AG: revenues & profitability 34
Figure 19: STADA Arzneimittel AG: assets & liabilities 34
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Threat of substitutes 19
Degree of rivalry 20
Leading Companies 21
Bayer AG 21
Novartis AG 25
Sanofi 29
STADA Arzneimittel AG 32
Appendix 35
Methodology 35
Industry associations 36
Related research 36
LIST OF TABLES
Table 1: Europe generics market value: $ million, 2008–12 9
Table 2: Europe generics market volume: % of total pharma volume, 2008–12 10
Table 3: Europe generics market geography segmentation: $ million, 2012 11
Table 4: Europe generics market value forecast: $ million, 2012–17 12
Table 5: Europe generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 21
Table 7: Bayer AG: key financials ($) 22
Table 8: Bayer AG: key financials (€) 22
Table 9: Bayer AG: key financial ratios 23
Table 10: Novartis AG: key facts 25
Table 11: Novartis AG: key financials ($) 26
Table 12: Novartis AG: key financial ratios 27
Table 13: Sanofi: key facts 29
Table 14: Sanofi: key financials ($) 30
Table 15: Sanofi: key financials (€) 30
Table 16: Sanofi: key financial ratios 30
Table 17: STADA Arzneimittel AG: key facts 32
Table 18: STADA Arzneimittel AG: key financials ($) 33
Table 19: STADA Arzneimittel AG: key financials (€) 33
Table 20: STADA Arzneimittel AG: key financial ratios 33
LIST OF FIGURES
Figure 1: Europe generics market value: $ million, 2008–12 9
Figure 2: Europe generics market volume: % of total pharma volume, 2008–12 10
Figure 3: Europe generics market geography segmentation: % share, by value, 2012 11
Figure 4: Europe generics market value forecast: $ million, 2012–17 12
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in Europe, 2012 14
Figure 7: Drivers of buyer power in the generics market in Europe, 2012 16
Figure 8: Drivers of supplier power in the generics market in Europe, 2012 17
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2012 18
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2012 19
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2012 20
Figure 12: Bayer AG: revenues & profitability 23
Figure 13: Bayer AG: assets & liabilities 24
Figure 14: Novartis AG: revenues & profitability 27
Figure 15: Novartis AG: assets & liabilities 28
Figure 16: Sanofi: revenues & profitability 31
Figure 17: Sanofi: assets & liabilities 31
Figure 18: STADA Arzneimittel AG: revenues & profitability 34
Figure 19: STADA Arzneimittel AG: assets & liabilities 34
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.